Australia's largest stock trading and investment forum Australia's #1 stock forum

KDR

0.00%

$1.90 kidman resources limited

Can KDR/ASIC prevent MZN profiteering from this legal saga?, page-179

First 179 Last

Share
Profile

Follow
aussieman

1,437 Posts.

162

20/05/17

13:58

Post #: 24811536
Share

Originally posted by farmlife ↑

Looking at the options I have read these two points
http://www.asx.com.au/documents/pro...rminations_10_July_2013_cash_adjusttments.pdf
section 13. Takeovers and Mergers under Schemes of Arrangement "The intrinsic value method is equivalent to the expiry of the options effectively brought forward to the last day of trading of the underlying security. No market is available in the underlying security and hence no market available in the options. Generally, the cash offer amount is used in lieu of the market value of the shares on the last day of trading. All terminations are determined on a case by case basis."

This would suggest the options have value, then in KDR announcement,

http://kidmanresources.com.au/live/...cember-2016-Quarterly-Activities-Report-1.pdf

The New Options are only exercisable by the holders of the New Options between 9.00 am and 5.00 pm on 30 April 2018.

As the Prospectus dated 23 March 2016 made it clear, the New Options cannot be exercised at any other time. In particular, there will be no acceleration of the exercise of the New Options even if there is a takeover bid for the Company or some other form of control transaction occurs.

This muddies the water and suggests the options may be worthless.
I have been hanging off buying the options, and only looked into this when speculation about take overs was raised. I am not sure now.

Does anyone have a clearer idea about these statements and how they affect options.

Expand

What will this week bring
A take over ?

I cannot wait for this crap to be over

Whats with the
Moscow comment
What are the thoughts on a buyout for a JV

Cheers

KDR Price at posting: 46.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

TYX

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

There are more pages in this discussion • 8 more messages in this thread...

First 179 Last

Add KDR (ASX) to my watchlist

Can KDR/ASIC prevent MZN profiteering from this legal saga?, page-179

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Banshee's historic trenches prove rich in antimony and gold for GDM

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

Cyclone signs MOU with Vale for development of Iron Bear play

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Featured News